Population
230 patients undergoing 246 operations for correction of acquired tricuspid valve disease, with all but…
Design
Cohort
Follow-up
up to 9 years
Authors
Loading...
May support homograft replacement in selected tricuspid disease; leaves open need for randomized durability comparisons.
Stented semilunar homograft valve replacement is a viable option for acquired tricuspid valve disease, demonstrating acceptable long-term survival and valve competence.
Barratt‐Boyes et al. (1988) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: